natgillin/translations-raw huggingface dataset:
A process for the preparation of a compound of the formula I wherein R1 is hydrogen or linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, comprising reacting a compound of the formula III with diimine, wherein the diimine is generated from hydroxylamine and hydroxylamine O-sulfonic acid in the presence of a base, from hydroxylamine-O-sulfonic acid in the presence of a base, from hydroxylamine and an acetic acid ester, from hydrazine and hydrogen peroxide, or from acid-catalyzed decarboxylation of azodicarboxylate, characterized in that the diastereomeric ratio of the crude products of diastereomer I to diastereomer IV is better than 90% to 10%. 
Postupak za pripremanje spoja formule I [image] u kojoj R1 je vodik ili ravni ili razgranati alkil s 1, 2, 3, 4, 5 ili 6 ugljikovih atoma ili cikloalkil s 3, 4, 5, 6 ili 7 ugljikovih atoma, koji sadrži reakciju spoja formule III [image] s diiminom, pri čemu se diimin tvori iz hidroksilamina i hidroksilamin O-sulfonske kiseline u prisutnosti baze, od hidroksilamin-O-sulfonske kiseline u prisutnosti baze, iz hidroksilamina i estera octene kiseline, iz hidrazina i vodikovog peroksida, ili iz kiselinom katalizirane dekarboksilacije azodikarboksilata, naznačen time, da je diastereomerni omjer sirovih proizvoda diastereomera I prema diastereomeru IV [image] bolji od 90% prema 10%.
A method for closing an end part (6) of an aluminium heating radiator element (1), comprising the steps of: 
Postupak zatvaranja krajnjeg dijela (6) elementa aluminijskog radijatora za grijanje (1), naznačen time, da obuhvaća sljedeće korake:
A method according to claim 1 or 2, wherein in the thermo-electric melting process the current supplied in the assembly (31) runs through the contact edges (23, 24) with an intensity such as to cause a raising of the temperature in the melting portions (21, 22), enough to melt said melting portions (21, 22). 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da u termoelektričnom procesu taljenja struja koja se isporučuje u sklopu (31) prolazi kroz kontaktne rubove (23, 24) s intenzitetom koji uzrokuje podizanje temperature u dijelovima za taljenje (21, 22), koje je dovoljno da se rastale navedeni dijelovi za taljenje (21, 22).
is a linker with the proviso that it is not CH1; 
je poveznica pod uvjetom da nije CH1;
VD2 is a second light chain variable domain; 
VD2 je druga varijabilna domena lakog lanca;
C is a light chain constant domain; 
C je konstantna domena lakog lanca;
n is independently 0 or 1; and wherein said first polypeptide chain comprises an amino acid sequence of SEQ ID NO: 212; wherein said second polypeptide chain comprises an amino acid sequence of SEQ ID NO: 215; and wherein the binding protein binds human IL-1β and human IL-1a. 
n je neovisno 0 ili 1; i pri čemu navedeni prvi polipeptidni lanac sadrži amino kiselinsku sekvencu iz SEQ ID NO: 212; pri čemu navedeni drugi polipeptidni lanac sadrži amino kiselinsku sekvencu iz SEQ ID NO: 215; i pri čemu vezujući protein veže ljudski IL-1β i ljudski IL-1a.
A vector comprising one or more isolated nucleic acid molecules according to Claim 8. 
Vektor naznačen time da sadrži jednu ili više jednu ili više izoliranih molekula nukleinske kiseline prema zahtjevu 8.
a sequence sharing at least 50% sequence identity with SEQ ID NO: 172, with the proviso that said sequence sharing sequence identity with SEQ ID NO: 172: 
sekvencu koja dijeli barem 50% identičnosti sekvence sa SEQ ID NO: 172, pod uvjetom da navedena sekvenca koja dijeli identičnosti sekvence sa SEQ ID NO: 172:
Method of non-therapeutically immunizing a non-human animal according to claim 12, wherein the non-human animal is a non-human mammal. 
Postupak ne-terapeutskog imuniziranja neljudske životinje prema zahtjevu 12, naznačen time da neljudska životinja je sisavac koji nije čovjek.
Method of non-therapeutically immunizing a non-human animal according to claim 13, wherein the non-human animal is selected from goat, mouse, rat and rabbit. 
Postupak ne-terapeutskog imuniziranja neljudske životinje prema zahtjevu 13, naznačen time da je neljudska životinja odabrana od koze, miša, štakora i zeca.
Method of isolating a cell according to claim 18, wherein the non-human animal is a non-human mammal. 
Postupak izoliranja stanice prema zahtjevu 18, naznačen time da neljudska životinja je sisavac koji nije čovjek.
Method of isolating a cell according to claim 19, wherein the non-human animal is selected from goat, mouse, rat and rabbit. 
Postupak izoliranja stanice prema zahtjevu 19, naznačen time da je neljudska životinja odabrana od koze, miša, štakora i zeca
A process for manufacturing the compound of formula I-2 said process comprising the reaction of the compound of formula I-1 wherein G1 represents halogen, or a salt of said compound, with ethylene glycol in the presence of a base, CHARACTERISED IN THAT, after the compound of formula I-2 has been obtained, a liquid-liquid extraction is performed, whereby methyl iso -butyl ketone is used to extract the compound of formula I-2 from an aqueous phase containing the products of the reaction of the compound of formula I-1 with ethylene glycol. 
Postupak za proizvodnju spoja sljedeće formule I-2: [image] I-2 pri čemu navedeni postupak obuhvaća reakciju spoja sljedeće formule I1: [image] I-1 gdje G1 predstavlja halogen, ili soli navedenog spoja, s etilen-glikolom u prisutnosti lužine, naznačen time, da se nakon što se dobije spoj formule I2, provodi ekstrakcija tekućina-tekućina, te se pritom upotrebljava metil-izobutil-keton za ekstrakciju spoja formule I2 iz vodene faze koja sadrži produkte reakcije spoja formule I1 s etilen-glikolom.
A process according to one of claims 1 to 9, wherein the compound of formula I-2 obtained after reaction of the compound of formula I-1 with ethylene glycol and the liquid-liquid extraction is crystallised by partial evaporation of methyl iso -butyl ketone from the organic phase collected, addition of an apolar aprotic organic solvent or of a mixture of apolar aprotic organic solvents to said organic phase, heating of the mixture thus obtained until complete solid dissolution is obtained and cooling down the mixture to obtain crystallisation of the compound of formula I-2. 
Postupak prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se spoj formule I2 koji se dobiva nakon reakcije spoja formule I1 s etilen-glikolom i ekstrakcije tekućina-tekućina, kristalizira pomoću djelomične evaporacije metil-izobutil-ketona iz sakupljene organske faze, pri čemu se dodaje nepolarno aprotonsko organsko otapalo ili smjesa nepolarnih aprotonskih organskih otapala u navedenu organsku fazu, a tako dobivena smjesa se zagrijava sve dok se ne dobije potpuno kruta otopina, te se potom smjesa rashlađuje kako bi se dobila kristalizacija spoja formule I2.
A process according to claim 10, wherein the compound of formula I-2 obtained after reaction of the compound of formula I-1 with ethylene glycol and the liquid-liquid extraction is crystallised by partial evaporation of methyl iso- butyl ketone from the organic phase collected, addition of heptane to said organic phase, heating of the mixture thus achieved until complete solid dissolution is achieved and cooling down the mixture to obtain crystallisation of the compound of formula I-2. 
Postupak prema zahtjevu 10, naznačen time, da se spoj formule I2 koji se dobiva nakon reakcije spoja formule I1 s etilen-glikolom i ekstrakcije tekućina-tekućina, kristalizira pomoću djelomične evaporacije metil-izobutil-ketona iz sakupljene organske faze, zatim se dodaje heptan u navedenu organsku fazu, a tako dobivena smjesa se zagrijava sve dok se ne dobije potpuno kruta otopina, te se potom smjesa rashlađuje kako bi se dobila kristalizacija spoja formule I2.
A process according to one of claims 1 to 11, wherein the proportion of residual ethylene glycol in the compound of formula I-2 obtained is below 500 ppm. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time, da udio ostatka etilen-glikola u dobivenom spoju formule I2, iznosi ispod 500 ppm.
Use according to claim 13 or 14, wherein the proportion of residual ethylene glycol in the compound of formula I-2 obtained following said use is below 500 ppm. 
Uporaba prema zahtjevu 13 ili 14, naznačena time, da udio ostatka etilen-glikola u spoju formule I2 koji se dobiva nakon navedene uporabe, iznosi ispod 500 ppm.
The method of claim 1, wherein said dsRNA duplex has a length of from 8 base pairs (bp) to 30 bp. 
Postupak prema zahtjevu 1, naznačen time, da navedena dsRNK-dupleks ima duljinu od osam baznih parova (bp) do 30 bp.
The method according to any one of the preceding claims wherein a protein transduction domain is covalently linked to the amino terminus of the Cas9 polypeptide, wherein said protein transduction domain facilitates the traversal of the Cas9 polypeptide from the cytosol to within an organelle of a cell. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da je domena transdukcije proteina kovalentno vezana na amino-završetak od polipeptida Cas9, pri čemu navedena domena transdukcije proteina olakšava poprečni prijelaz polipeptida Cas9, od citosola do unutar organele stanice.
The method according to any one of claims 1-7 wherein a protein transduction domain is covalently linked to the carboxyl terminus of the Cas9 polypeptide, wherein said protein transduction domain facilitates the traversal of the Cas9 polypeptide from the cytosol to within an organelle of a cell. A composition comprising: 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je domena transdukcije proteina kovalentno vezana na karboksilni završetak od polipeptida Cas9, pri čemu navedena domena transdukcije proteina olakšava poprečni prijelaz polipeptida Cas9, od citosola do unutar organele stanice.
The composition of claim 10, wherein a protein transduction domain is covalently linked to the carboxyl terminus of the Cas9 polypeptide, wherein said protein transduction domain facilitates the traversal of the Cas9 polypeptide from the cytosol to within an organelle of a cell. 
Sastav prema zahtjevu 10, naznačen time, da je domena transdukcije proteina kovalentno vezana na amino-završetak od polipeptida Cas9, pri čemu navedena domena transdukcije proteina olakšava poprečni prijelaz polipeptida Cas9, od citosola do unutar organele stanice.
The composition of any one of claims 10-12, wherein (a) the Cas9 polypeptide, or the polynucleotide encoding said Cas9 polypeptide, and (b) the single-molecule DNA-targeting RNA, or the DNA polynucleotide encoding said DNA-targeting RNA are in a cell in vitro or ex vivo, wherein the cell is not a human germ cell. 
Sastav prema bilo kojem od zahtjeva 10 do 12, naznačen time, da se (a) polipeptid Cas9, ili polinukleotid koji kodira navedeni polipeptid Cas9, i (b) RNK jednostruke molekule koja cilja na DNK, ili DNK-polinukleotid koji kodira navedenu RNK koja cilja na DNK, nalaze u stanici in vitro ili ex vivo, pri čemu stanica nije ljudski zametak.
a protein-binding segment that interacts with a Cas9 protein, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides. 
segment koji veže protein, te koji djeluje zajedno s proteinom Cas9, pri čemu segment koji veže protein, obuhvaća dva komplementarna nukleotidna odsjeka koji hibridiziraju kako bi stvorili RNK dvostruke strukture (dsRNK)-dupleks, te su pritom navedena dva komplementarna nukleotidna odsjeka kovalentno vezana putem interventnih nukleotida.
a protein-binding segment that interacts with a Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides; 
segment koji veže protein, te koji djeluje zajedno s polipeptidom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna nukleotidna odsjeka koji hibridiziraju kako bi tvorili RNK dvostruke strukture (dsRNK)-dupleks, te su pritom dva komplementarna nukleotidna odsjeka kovalentno vezana putem interventnih nukleotida;
The one or more nucleic acids of claim 15, wherein said nucleic acids are one or more recombinant expression vectors. 
Jedna ili više nukleinskih kiselina prema zahtjevu 15, naznačene time, da navedene nukleinske kiseline predstavljaju jednoga ili više rekombinantnih vektora ekspresije.
a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides, and wherein (a) and (b) are in the same or separate containers. 
segment koji veže protein, te koji djeluje zajedno s navedenim polipeptidom Cas9, gdje segment koji veže protein obuhvaća dva komplementarna nukleotidna odsjeka koji hibridiziraju kako bi tvorili RNK dvostruke strukture (dsRNK)-dupleks, te time, da su navedena dva komplementarna nukleotidna odsjeka kovalentno vezana putem interventnih nukleotida; te time, da su (a) i (b) u zajedničkom spremniku ili u odvojenim spremnicima.
The composition of any one of claims 10-13, the single-molecule DNA-targeting RNA or polynucleotide encoding said single-molecule DNA-targeting RNA of claim 14, the one or more nucleic acids of any of claims 15-17 or the kit of claim 18, wherein said dsRNA duplex has a length of from 8 base pairs (bp) to 30 bp. 
Sastav prema bilo kojem od zahtjeva 10 do 13, RNK jednostruke molekule koja cilja na DNK ili polinukleotid koji kodira navedenu RNK jednostruke molekule koja cilja na DNK, prema zahtjevu 14, jedna ili više nukleinskih kiselina prema bilo kojem od zahtjeva 15 do 17, ili garnitura prema zahtjevu 18, naznačeni time, da navedena dsRNK-dupleks ima duljinu od osam baznih parova (bp) do 30 bp.
The composition of any one of claims 10-13, 19 or 20, the single-molecule DNA-targeting RNA or polynucleotide encoding said single-molecule DNA-targeting RNA of any of claims 14, 19 or 20, the one or more nucleic acids of any one of claims 15-17, 19 or 20, or the kit of any one of claims 18, 19 or 20, wherein the target DNA is present in a bacterial cell, an archaeal cell, a single-cell eukaryotic organism, a plant cell, a cell from an invertebrate animal, or a cell from a vertebrate animal. 
Sastav prema bilo kojem od zahtjeva 10 do 13, 19 ili 20, RNK jednostruke molekule koja cilja na DNK ili polinukleotid koji kodira navedenu RNK jednostruke molekule koja cilja na DNK, prema zahtjevima 14, 19 ili 20, jedna ili više nukleinskih kiselina prema bilo kojem od zahtjeva 15 do 17 i 19 ili 20, ili garnitura prema zahtjevima 18, 19 ili 20, naznačeni time, da je ciljana DNK prisutna u bakterijskoj stanici, archaea-bakterijskoj stanici, jednostaničnom eukariotskom organizmu, biljnoj stanici, životinjskoj stanici od beskičmenjaka, ili u životinjskoj stanici od kičmenjaka.
The LNG fuel tank system according to claims 1 and 2, characterized in that the vapour pressure within the LNG fuel tank (4) is controlled to be below about 0,7 bar gauge. 
Sustav spremnika za LNG gorivo prema zahtjevima 1 i 2, naznačen time da se pritisak pare unutar spremnika za LNG gorivo (4) kontrolira da bude ispod oko 0,7 bara.
The LNG fuel tank system according to any preceding claim, characterized in that a compressor (5) which is situated in a suction and compression line (6, 7) extending between the LNG fuel tank (4) and gas vessel (8) is used as to limit the LNG fuel tank pressure during bunkering and pressure relieving the LNG fuel tank. 
Sustav spremnika za LNG gorivo prema bilo kojem prethodnom zahtjevu, naznačen time da se kompresor (5) koji je smješten u usisnom i tlačnom vodu (6, 7) proteže između spremnika za LNG gorivo (4) i posude za plin (8) koristi za ograničavanje pritiska u spremniku za LNG gorivo tijekom skladištenja i oslobađanje pritiska spremnika za LNG gorivo.
The LNG fuel tank system according to claim 5, characterized in that propulsion gas from the gas vessel (8) is supplied via a gas line (11) passing a heater (13). 
Sustav spremnika za LNG gorivo prema zahtjevu 5, naznačen time da se pogonski plin iz spremnika plina (8) dovodi putem plinskog voda (11) koji prolazi grijač (13).
The LNG fuel tank system according to claim 6, characterized in that the gas flow pressure is reduced using a Joule-Thompson valve (10) arranged upstream the heater (13). 
Sustav spremnika za LNG gorivo prema zahtjevu 6, naznačen time da se pritisak struje plina smanjuje korištenjem Joule-Thompsonovog ventila (10) smještenog uzvodno od grijača (13).
A conditional replication defective cytomegalovirus (CMV) comprising: 
Citomegalovirus (CMV) s uvjetno defektnom replikacijom koji sadrži:
a nucleic acid encoding a fusion protein between an essential protein and a destabilizing protein, wherein the essential protein is selected from the group consisting of IE1/2, UL51, UL52, UL79 and UL84 wherein the destabilizing protein is either FK506-binding protein (FKBP) or an FKBP derivative, wherein the FKBP derivative is FKBP comprising one or more amino acid substitutions selected from the group consisting of: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K105I and L106P, and wherein the wild type essential protein is no longer present. 
nukleinsku kiselinu koja kodira fuzijski protein između esencijalnog proteina i destabilizirajućeg proteina, pri čemu je esencijalni protein izabran iz grupe koja se sastoji od IE1/2, UL51, UL52, UL79 i UL84, pri čemu, destabilizirajući protein je FK506-vezujući protein (FKBP) ili FKBP derivat, pri čemu, FKBP derivat je FKBP koji sadrži jednu ili više aminokiselinskih supstitucija izabranih iz grupe koja se sastoji od: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K105I i L106P, i pri čemu divlji tip esencijalnog proteina nije više prisutan.
A compound of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate thereof, wherein: ring A is selected from aryl and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NH, N(C1-4 alkyl), S(O)p, and O, wherein said aryl and heterocycle are optionally substituted with R1; 
Spoj sa formulom (I): [image] ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, ili solvat tog spoja, gdje: prsten A je odabran od arila i 5- do 6-članog heterociklusa koji sadrži: ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NH, N(C1-4 alkil), S(O)p, i O, gdje su spomenuti aril i heterociklus po izboru supstituirani sa R1;
ring B is a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NH, S(O)p, and O, wherein said heterocycle is optionally substituted with R10; 
prsten B je 5- do 6-člani heterociklus koji sadrži: ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NH, S(O)p, i O, gdje je spomenuti heterociklus po izboru supstituiran sa R10;
alternatively, R2 and R3, together with the atoms to which they are directly or indirectly attached, form a ring wherein said ring is optionally substituted with =O; 
alternativno, R2 i R3, zajedno sa atomima za koje su direktno ili indirektno vezani, formiraju prsten pri čemu je spomenuti prsten po izboru supstituiran sa =O;
provided the following compounds are excluded and 
pod uvjetom da su isključeni sljedeća spojevi [image] i [image]
The compound of claim 1 having Formula (II): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate thereof, wherein: ring A is selected from aryl and a 6-membered heterocycle comprising: carbon atoms and 1-3 heteroatoms selected from N, NH, and N(C1-4 alkyl); 
Spoj patentnog zahtjeva 1 koje ima Formulu (II): [image] ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, ili solvat tog spoja, gdje: prsten A je odabran od arila i 6-članog heterociklusa koji sadrži: ugljikove atome i 1-3 heteroatoma koji su odabrani od N, NH, i N(C1-4 alkil);
ring B is selected from imidazole, pyridine, pyridone, and pyridazine; 
prsten B je odabran od imidazola, piridina, piridona, i piridazina;
The compound of claim 2, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate thereof, wherein: ring A is selected from phenyl and piperidine; is independently selected from and 
Spoj patentnog zahtjeva 2, ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, ili solvat tog spoja, gdje: prsten A je odabran od fenila i piperidina; [image] je nezavisno odabran od [image] [image] [image] i
is selected from H, halogen, and CN. 
je odabran od H, halogena, i CN.
is selected from H, halogen and CN. 
je odabran od H, halogen i CN.
is selected from H and CN. 
je odabran od H i CN.
The compound of claim 5 having Formula (V): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate thereof, wherein: 
Spoj patentnog zahtjeva 5 koje ima Formulu (V): [image] ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, ili solvat tog spoja, gdje:
is selected from H, methyl, ethyl, and isopropyl. 
je odabran od H, metil, etil, i izopropil.
The compound of claim 4 having Formula (VI): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate thereof, wherein: 
Spoj patentnog zahtjeva 4 koje ima Formulu (VI): [image] ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, ili solvat tog spoja, gdje:
A pharmaceutical composition comprising one or more compounds according to any one of claims 1-8 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutska kompozicija koja sadrži jedno ili više spoja u skladu sa bilo kojim od patentnih zahtjeva 1-8 i farmaceutski prihvatljiv nosač ili otapalo.
A compound of any one of claims 1-8, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in therapy. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-8, ili stereoizomer, tautomer, ili farmaceutski prihvatljiva sol tog spoja, za primjenu u liječenju.
A therapeutically effective amount of a compound of any one of claims 1-8, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of a thromboembolic disorder. 
Terapijski efikasna količina spoja iz bilo kojeg od patentnih zahtjeva 1-8, ili stereoizomera, tautomera, ili farmaceutski prihvatljive soli tog spoja, za primjenu u liječenju i/ili profilaksi tromboembolijskog poremećaja.
A therapeutically effective amount of a compound of any one of claims 1-8, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use according to claim 11, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart or in the peripheral circulation. 
Terapijski efikasna količina spoja bilo kojeg od patentnih zahtjeva 1-8, ili stereoizomera, tautomera, ili farmaceutski prihvatljive soli tog spoja, za primjenu prema patentnom zahtjevu 11, gdje tromboembolijski poremećaj je odabran iz grupe koja se sastoji od arterijskih kardiovaskularnih tromboembolijskih poremećaja, venskih kardiovaskularnih tromboembolijskih poremećaja i tromboembolijskih poremećaja u komorama srca ili u perifernoj cirkulaciji.